Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 5;23(3):581.
doi: 10.3390/molecules23030581.

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

Ján Kozempel  1 , Olga Mokhodoeva  2 , Martin Vlk  3
Affiliations
Review

Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators

Ján Kozempel et al. Molecules. .

Abstract

This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments.

Keywords: 223Ra; actinium; alpha particle; astatine; bismuth; decay; in vivo generators; nuclear recoil; radium; targeted alpha therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funding sponsors had no role in the interpretation of data, in the writing of the manuscript, and in the decision to publish the results.

Figures

Figure 1
Figure 1
(a) Log/log plot of linear-energy transfer (LET) of α particles and 219Rn ions vs. their path (distance) in water up to the rest; (b) Semi-log 3D plot of final at rest positions of α particles and 219Rn ions with their xy, xz and yz plane projections. The recoil, in fact, travels in opposite direction to the emitted α particle (common decay-event origin at x,y,z = 0,0,0).
Figure 2
Figure 2
Chemical formulas of cyclic chelators.
Figure 3
Figure 3
Chemical formulas of TCMC and CHXA”-DTPA chelators.
Figure 4
Figure 4
Selected pharmacokinetics of 213Bi-DOTATATE in H69 (A–C) and CA20948 (D–F) tumor-bearing animals: uptake in tumors (A,D) and kidney (B,E), and radioactivity in blood (C,F) [63].
Figure 5
Figure 5
68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) scans of a patient comparing the initial tumor spread (A); restaging after 2 cycles of β− emitting 177Lu-PSMA-617 reveals progression (B). In contrast, restaging after second (C) and third (D) cycles of α emitting 225Ac-PSMA-617 shows impressive response. This research was originally published in JNM. Kratochwil et al. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J. Nucl. Med. 2016, 57(12), 1941–1944. © by the Society of Nuclear Medicine and Molecular Imaging, Inc. [4].
See this image and copyright information in PMC

References

    1. Song H., Senthamizhchelvan S., Hobbs R.F., Sgouros G. Alpha Particle Emitter Radiolabeled Antibody for Metastatic Cancer: What Can We Learn from Heavy Ion Beam Radiobiology? Antibodies. 2012;1:124–148. doi: 10.3390/antib1020124. - DOI
    1. Borchardt P.E., Yuan R.R., Miederer M., McDevitt M.R., Scheinberg D.A. Targeted Actinium-225 In Vivo Generators for Therapy of Ovarian Cancer. Cancer Res. 2003;63:5084–5090. - PubMed
    1. Jaggi J.S., Kappel B.J., McDevitt M.R., Sgouros G., Flombaum C.D., Cabassa C., Scheinberg D.A. Efforts to control the errant products of a targeted in vivo generator. Cancer Res. 2005;65:4888–4895. doi: 10.1158/0008-5472.CAN-04-3096. - DOI - PubMed
    1. Kratochwil C., Bruchertseifer F., Giesel F.L., Weis M., Verburg F.A., Mottaghy F., Kopka K., Apostolidis C., Habekorn U., Morgenstern A. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J. Nucl. Med. 2016;57:1941–1944. doi: 10.2967/jnumed.116.178673. - DOI - PubMed
    1. Kratochwil C., Bruchertseifer F., Rathke H., Bronzel M., Apostolidis C., Weichert W., Haberkorn U., Giesel F.L., Morgenstern A. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J. Nucl. Med. 2017;58:1624–1631. doi: 10.2967/jnumed.117.191395. - DOI - PubMed

MeSH terms

LinkOut - more resources